Mark A. Velleca
2018 - G1 Therapeutics
In 2018, Mark A. Velleca earned a total compensation of $1.9M as Chief Executive Officer and President at G1 Therapeutics, a 159% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $321,875 |
---|---|
Option Awards | $1,044,529 |
Salary | $515,000 |
Other | $33,250 |
Total | $1,914,654 |
Velleca received $1M in option awards, accounting for 55% of the total pay in 2018.
Velleca also received $321.9K in non-equity incentive plan, $515K in salary and $33.3K in other compensation.
Rankings
In 2018, Mark A. Velleca's compensation ranked 5,969th out of 14,244 executives tracked by ExecPay. In other words, Velleca earned more than 58.1% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 5,969 | 58th |
Manufacturing | 2,271 | 61st |
Chemicals And Allied Products | 850 | 60th |
Drugs | 711 | 61st |
Pharmaceutical Preparations | 554 | 60th |
Velleca's colleagues
We found five more compensation records of executives who worked with Mark A. Velleca at G1 Therapeutics in 2018.
News
Black Diamond Therapeutics CEO Mark Velleca receives $2.9M in 2023
April 24, 2024
G1 Therapeutics CEO Mark Velleca's 2020 pay stays at $4M
April 28, 2021
G1 Therapeutics Chief Business Officer Mark Avagliano receives $5.5M in 2019
April 24, 2020
G1 Therapeutics Chief Commercial Officer John Demaree receives $7.5M in 2018
April 30, 2019